References
- Hofmann SC, Juratli HA, Eming R. Bullous autoimmune dermatoses. J Dtsch Dermatol Ges. 2018;16(11):1339–1358.
- Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris–incidence and mortality in the UK: population based cohort study. BMJ (Clinical Research ed). 2008;337(jul09 1):a180.
- Centers for Disease Control and Prevention. NAMCS Estimation Procedures; [cited 2021 Jan 21]. Available from: https://www.cdc.gov/nchs/ahcd/ahcd_estimation_procedures.htm
- Why population aging matters a global perspective. [cited 2020 Oct 23]. Available from: https://www.nia.nih.gov/sites/default/files/2017-06/WPAM.pdf
- Brick KE, Weaver CH, Lohse CM, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92–99.
- Di Lernia V, Casanova DM, Goldust M, et al. Pemphigus vulgaris and bullous pemphigoid: update on diagnosis and treatment. Dermatol Pract Concept. 2020;10(3):e2020050.
- Drug Label: Rituxan (rituximab). [cited 2020 Nov 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5450lbl.pdf